hotspot -WSS

hotspot

author：explore 2025-10-02 16:00:48 - browse：129

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： 3 questions for the future of Biden's cancer moonshot

WSS

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Phenylephrine and the overlooked value of the placebo effect

Prior authorization will have to move faster under new Biden rule

Why doctors need education on FDA device approval process

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Test for long Covid? Researchers find new clue in blood samples

Hepatitis C has a cure — but many Americans still lack access to it

Dewpoint Therapeutics lays off staff after losing partnerships

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

My yearlong odyssey to get my son’s ADHD medication covered

Guidelines to prevent youth baseball injuries need more muscle

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Virginia high school admissions case could be legal follow

How digital therapeutics firms are pivoting after Pear's bankruptcy

hotspot

Bristol 'take

When women are denied an abortion, their children fare worse than peers

Bill would stop addiction treatment from triggering child abuse inquiry

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

New brain studies show LSD's effects on the brain in full color

Medicare Advantage today, explained in one chart

knowledge

knowledge

hotspot

focus